DOCSLIB.ORG

U.S. Department of Labor, Office of Workers

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
U.S. Department of Labor, Office of Workers U.S. DEPARTMENT OF LABOR, OFFICE OF WORKERS' COMPENSATION PROGRAMS 2010 FEE SCHEDULE MODIFIER LEVEL TABLES Effective Date: 07/18/2010 Last Update: 03/31/2011 File: fs10_mod_table.xls Sort by CPT/HCPCS CPT/HCPCS MOD MOD LEV DESCRIPTION 00100 291 Anest for proced on integ sys - head/or saliv glands 00102 291 Anesthesia for plastic repair of cleft lip 00103 291 Anesthesia for bepharoplasty 00104 291 Anesthesia for electroconvulsive therapy 00120 291 Anest; proc-esternal/middle/inner ear, inc biopsy nos 00124 291 Anesthesia for otoscopy 00126 291 Anesthesia for tympanotomy 00140 291 Anesthesia for procedures on eye; nos 00142 291 Anesthesia for procedures on eye; lens surgery 00144 291 Anest; procedures on eye; corneal transplant 00145 291 Anesthesia for procedures on eye; vitrectomy 00147 291 Anesthesia for iridectomy 00148 291 Anesthesia for procedures on eye; opthalmoscopy 00160 291 Anest; proc-nose and accessory sinuses; nos 00162 291 Anest; proced-nose/accesory sinuses; rad surg 00164 291 Anesth-proced on nose & access sinuses; biop/soft tis 00170 291 Anesthesia for intraoral procedures, incl biopsy; nos 00172 291 Anesth-intraoral proced, w/biop; repair-cleft palate 00174 291 Anest; intraoral pro-w/biop-ex/retropharyngeal tumor 00176 291 Anesth-intraoral proced, w/biopsy; rad surg 00190 291 Anesthesia for procedures on facial bones; nos 00192 291 Anest - proced on facial bones; rad surg 00210 291 Anesthesia for intracranial proacedures nos 00211 291 Anesth, cran surg, hemotoma 00212 291 Anest; intracranial procedures; subdural taps 00214 291 Anesthesia for intracranial procedures; burr holes 00215 291 Anesthesia for skull fracture 00216 291 Anesthesia-intracranial proced; vascular 00218 291 Anesth-intracranial proced, in sitting position 00220 291 Anest - intracranial proced; spinal fluid shunting proc 00222 291 Anest - intracranial proc; electrocoag-cranial nerve 00300 291 Anest; proc-integ sys of neck, incl subcu tissue 00320 291 Anest-proced: esoph/thy/lar/trac/lymph nos 00322 291 Anest proced on neck: needle biopsy of thyroid 00350 291 Anesth; proc-on major vessels of neck; nos 00352 291 Anesth-proc on maj vessels of neck; simple ligation 00400 291 Anesth; proc on ant integ sys-chest a/subcu tise 00402 291 Anest; proc-ant integ sys of chest; reconstr on breast 00404 291 Anest; proc-ant integ sys of chest; radical/mod rad; breast 00406 291 Anest; ant integ sys chest; rad/mod rad proc; breast w/node disse 00410 291 Anest; proc ant integ chest; elec convers of arrhythmias 00450 291 Anest; proc-on clavicle and scapula; nos 00452 291 Anest; proc-clavicle & scapula; rad surg 00454 291 Anesthesia for procedures on clavicle, biopsy 00470 291 Anesthesia for partial rib resection nos 00472 291 Anest; partial rib resection, thoracoplasty (any type) 00474 291 Anesthesia for partial rib resection, radical proced 00500 291 Anesthesia for all procedures on esophagus 00520 291 Anest for closed chest proc nos 00522 291 Anest - closed chest proced; needle biopsy-pleura 00524 291 Anest for closed chest procedure; pneumocentesis 00528 291 Anest for closed chest procedure; mediastinoscopy 00529 291 Anest, closed chest procedure; medi 00530 291 Anesthesia for permanent transvenous pacemaker insertion 00532 291 Anesthesia for accesss to central venous circula 00534 291 Anest-transven insert/replace-cardioverter/debfib 00537 291 Anest for cardiac electrophysiologic procedures 00539 291 Anest; tracheobronchial reconstruction 00540 291 Anest; thoracot proced-lungs/pleura/dia/media nos 00541 291 Anest; thoracot proced; one lung ventilation 00542 291 Anest; thoracotomy procedure - decortication 00546 291 Anesth-thoracot; pul resection w/thoracoplasty 00548 291 Anesth-thoracotomy; repair-trauma to trachea/bronchi 00550 291 Anesthesia for sternal debridement 00560 291 Anest-heart/pericard/great ves-chest; w/o pump oxygenator, ped 00562 291 Anest-heart/pericard/great ves-chest; w/pump oxygenator 00563 291 Anest-heart/pericard/great ves-chest; w/pump oxyg w/hypotherm 00566 291 Anest for direct coronary artery bypass graft w/out pump oxyg 00567 291 Anesth, cabg w/pump 00580 291 Anesthesia for heart transplant-heart/lung 00600 291 Anesth for proced on cerv spine/cord; nos 00604 291 Anesth-post cerv laminect-sitting position 00620 291 Anesthesia-proced on thoracic spine/cord; nos 00622 291 Anesthesia for thoracolumbar sympathectomy 00625 291 Anes spine tranthor w/o vent 00626 291 Anes, spine transthor w/vent 00630 291 Anesthesia for procedures in lumbar region (nos) 00632 291 Anesthesia for lumbar sympathectomy 00634 291 Anesth-procedures in lum region; chemonucleolysis 00635 291 Anesth-procedures in lum region; diag/therapeutic lum puncture 00640 291 Anesth-manip of spine; closed proced on spine 00670 291 Anesth-ext spine/spinal cord proced 00700 291 Anesth-proced on upper ant abdom wall; (nos) 00702 291 Anesthesia for percutaneous liver biopsy 00730 291 Anesth-procedures on upper post abdominal wall 00740 291 Anesth-upper gastrointestinal endoscopic proced 00750 291 Anesthesia for hernia repairs in upper abdomen; (nos) 00752 291 Anesth-repair lum/ventral hernias/wound dehiscence 00754 291 Anesth-hernia repairs-up abdomen; omphalocele 00756 291 Anesth-transabdominal repair-diaphragmatic hernia 00770 291 Anesth-all procedures-major abdominal blood ves 00790 291 Anesth-intraperitoneal proced-up abdo, w/laparos nos 00792 291 Anesth-intraperitoneal proced up abdo-partial hepatectomy 00794 291 Anesth-intraperitoneal pro/up abdo; pancreatect/part/tot 00796 291 Anesth-intraperitoneal pro up abdo, shunts/liver transplant 00797 291 Anesth-intraperitoneal pro up abdo, gastric restrict procedure 00800 291 Anesth-pro low ant abdom wall nos 00802 291 Anesth-pro low ant abdom wall; panniculectomy 00810 291 Anesthesia for intestinal endoscopic procedures 00820 291 Anesth-pro on low post abdominal wall 00830 291 Anesthesia for hernia repairs in lower abdomen; (nos) 00832 291 Anesth-hernia repair, ventral & incisional hernias 00840 291 Anesth-intraperitoneal proced low abdo w/laparos; nos 00842 291 Anesthesia for amniocentesis 00844 291 Anesthesia for abdominoperitoneal resection 00846 291 Anesthesia for radical hysterectomy 00848 291 Anesthesia for pelvic exentration 00851 291 Anesthesia for tubal ligation 00860 291 Anesth-extraperitoneal low abdo, w/urinary tract-nos 00862 291 Anesth-renal proced w/upper 1/3 ureter/donor nephrect 00864 291 Aanesthesia for total cystectomy 00865 291 Anest - extraperitoneal proced-lower abd; rad prostatectomy 00866 291 Anesthesia for adrenalectomy 00868 291 Anesthesia for renal transplant (recipient) 00870 291 Anesthesia for cystolithiotomy 00872 291 Anesth-lithotripsy/extracorp shock wave-w/h20 bath 00873 291 Anesth-lithotripsy/extracorp shock wave-w/o h20 bath 00880 291 Anesth-proced on maj low abdom ves; nos 00882 291 Anesth-proced on maj low abdom ves; infer vena cava liga 00902 291 Anesthesia for anorectal procedures 00904 291 Anesthesia for radical perineal procedure 00906 291 Anesthesia for vulvectomy 00908 291 Anesthesia for perineal prostatectomy 00910 291 Anesthesia for transurethral procedures 00912 291 Anesthesia for transurethral resection of bladder 00914 291 Anesthesia for transurethral resection of prostate 00916 291 Anesthesia for post-transurethral resection bleeding 00918 291 Anesthesia for transurethral procedures,w/fragmenta 00920 291 Anesthesia-proced on male genital ext genitalia, nos 00921 291 Anesthesia-vasectomy, unilat/bilateral 00922 291 Anesthesia for procedures on seminal vesicles 00924 291 Anesth-proced on undescended testis, unilat/bilat 00926 291 Anesthesia for radical orchiectomy, inguinal 00928 291 Anesthesia for radical orchiectomy, abdominal 00930 291 Anesthesia for orchiopexy, unilateral or bilateral 00932 291 Anesthesia for complete amputation of penis 00934 291 Anesth-radical amputat-penis w/bilat ing lymphaden 00936 291 Anesth-rad amputa-penis w/bilat inguinal/iliac lymphaden 00938 291 Anesth-insertion of penile prosthesis-perineal ap 00940 291 Anesth-vaginal procedures, nos 00942 291 Anesth-for colpotomy, colpectomy, colporrhaphy 00944 291 Anesthesia for vaginal hysterectomy 00948 291 Anesthesia for cervical cerclage 00950 291 Anesthesia culdoscopy 00952 291 Anesthesia for hysteroscopy 01112 291 Anesthesia-bone marrow aspiration/biopsy, iliac crest 01120 291 Anesthesia for procedures on bony pelvis 01130 291 Anesthesia for body cast application or revision 01140 291 Anesth for interpelviabdom amputation (hindquarter) 01150 291 Anesth-rad proced tumor of pelvis, ex hindqtr amputation 01160 291 Anesth-closed pro, involv symphysis pubis/sacroiliac jnt 01170 291 Anesth-open pro involv symphysis pubis/sacroiliac jnt 01173 291 Anesth-open repair, FX disrupt 01180 291 Anesthesia for obturator neurectomy, extrapelvic 01190 291 Anesthesia for obturator neurectomy, intrapelvic 01200 291 Anesthesia for all closed procedures involving hip joint 01202 291 Anesthesia for arthroscopic procedures of hip joint 01210 291 Anesthesia for open procedures involving hip joint; (nos) 01212 291 Anesthesia for hip disarticulation 01214 291 Anesthesia for total hip replacement or revision 01215 291 Anesthesia for revision of total hip arthroplasty 01220 291 Anesth-all closed proced involv up 2/3 of femur-nos 01230 291 Anesth-all open proced involv up 2/3 of femur nos 01232 291 Anesth-open proced involv up 2/3 of femur; amputation 01234 291 Anesth-open proced involv up 2/3 of femur; rad resect 01250 291 Anesth-all proced nerves/mus/ten/fasc/bur-up leg 01260 291 Anesth-all proced involv veins of up leg incl exploration
Load more

Recommended publications
  • The Activation of the Glucagon-Like Peptide-1 (GLP-1) Receptor by Peptide and Non-Peptide Ligands
    The Activation of the Glucagon-Like Peptide-1 (GLP-1) Receptor by Peptide and Non-Peptide Ligands Clare Louise Wishart Submitted in accordance with the requirements for the degree of Doctor of Philosophy of Science University of Leeds School of Biomedical Sciences Faculty of Biological Sciences September 2013 I Intellectual Property and Publication Statements The candidate confirms that the work submitted is her own and that appropriate credit has been given where reference has been made to the work of others. This copy has been supplied on the understanding that it is copyright material and that no quotation from the thesis may be published without proper acknowledgement. The right of Clare Louise Wishart to be identified as Author of this work has been asserted by her in accordance with the Copyright, Designs and Patents Act 1988. © 2013 The University of Leeds and Clare Louise Wishart. II Acknowledgments Firstly I would like to offer my sincerest thanks and gratitude to my supervisor, Dr. Dan Donnelly, who has been nothing but encouraging and engaging from day one. I have thoroughly enjoyed every moment of working alongside him and learning from his guidance and wisdom. My thanks go to my academic assessor Professor Paul Milner whom I have known for several years, and during my time at the University of Leeds he has offered me invaluable advice and inspiration. Additionally I would like to thank my academic project advisor Dr. Michael Harrison for his friendship, help and advice. I would like to thank Dr. Rosalind Mann and Dr. Elsayed Nasr for welcoming me into the lab as a new PhD student and sharing their experimental techniques with me, these techniques have helped me no end in my time as a research student.
    [Show full text]
  • List of Approved Ndas for Biological Products That Were Deemed to Be Blas on March 23, 2020
    List of Approved NDAs for Biological Products That Were Deemed to be BLAs on March 23, 2020 On March 23, 2020, an approved application for a biological product under section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) was deemed to be a license for the biological product under section 351 of the Public Health Service Act (PHS Act) (see section 7002(e)(4)(A) of the Biologics Price Competition and Innovation Act of 2009). To enhance transparency and facilitate planning for the March 23, 2020, transition date, FDA compiled a preliminary list of approved applications for biological products under the FD&C Act that were listed in FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations (the Orange Book) and that would be affected by this transition provision. FDA posted this list on the FDA website in December 2018, and periodically updated this list before the March 23, 2020, transition date. The September 2019 update to this preliminary list added certain administratively closed applications related to approved applications for biological products that were on the December 2018 version of this list. The January 2020 update to the preliminary list reflected a change to the definition of “biological product” made by the Further Consolidated Appropriations Act, 2020, which was enacted on December 20, 2019. Section 605 of this Act further amended the definition of a “biological product” in section 351(i) of the PHS Act to remove the parenthetical “(except any chemically synthesized polypeptide)” from the statutory category of “protein.” FDA has provided below a list of each approved application for a biological product under the FD&C Act that was deemed to be a license (i.e., an approved biologics license application (BLA)) for the biological product on March 23, 2020.
    [Show full text]
  • Corticorelin Acetate, a Synthetic Corticotropin-Releasing Factor with Preclinical Antitumor Activity, Alone and with Bevacizumab, Against Human Brain Tumor Models
    ANTICANCER RESEARCH 30: 5037-5042 (2010) Corticorelin Acetate, a Synthetic Corticotropin-releasing Factor with Preclinical Antitumor Activity, alone and with Bevacizumab, against Human Brain Tumor Models IDOIA GAMEZ1, ROBERT P. RYAN1 and STEPHEN T. KEIR2 1Celtic Pharmaceutical Development Services America, Inc., New York, NY 10022, U.S.A.; 2The Preston Robert Tisch Brain Tumor Center, Duke University, Durham, NC 27710, U.S.A. Abstract. Background: Corticorelin acetate (CrA) is a brain tumors. The cause of PBE is believed to result in part synthetic form of corticotropin-releasing factor that is from the leakage of edematous brain tumor fluid from currently undergoing clinical trials in the treatment of abnormal tumor vasculature into the surrounding tissue (1, peritumoral brain edema (PBE). This study preclinically 2). The mechanism(s) of action by which CrA exerts its investigated its potential as an antitumor agent against beneficial effect in the therapy of PBE has not been human brain tumor xenografts. Materials and Methods: The elucidated, but two factors appear to be relevant: decreased in vivo efficacy of CrA as a single agent and in combination vascular leakage and preserved integrity of the endothelial with the antiangiogenic agent, bevacizumab, was examined cells, which ultimately helps to maintain the blood-brain in three different patient-derived human brain tumor barrier (3, 4). xenografts implanted orthotopically (intracranially) or CrA appears to mediate its activity through two subtypes subcutaneously in athymic mice. Results: CrA significantly of G-protein coupled receptors: CRF receptor-1 (CRFR1) increased the lifespan of mice implanted orthotopically with and CRF receptor-2 (CRFR2) (5). These CRFRs are widely two different pediatric brain tumor xenograft models.
    [Show full text]
  • BCBSVT Specialty Drug List Effective 2021.07.01.Xlsx
    Effective Date: 07/01/2021 SPECIALTY DRUG LIST Revised Date: 05/07/2021 DOSAGE EXCLUDED ON NATIONAL DRUG CLASS DRUG NAME GENERIC NAME FORM PERFORMANCE FORMULARY ANEMIA ARANESP SOLN DARBEPOETIN ALFA SOLN INJ ANEMIA ARANESP SOSY DARBEPOETIN ALFA SOLN PREFILLED SYRINGE ANEMIA EPOGEN SOLN EPOETIN ALFA INJ X ANEMIA PROCRIT SOLN EPOETIN ALFA INJ X ANEMIA REBLOZYL SOLR LUSPATERCEPT-AAMT FOR SUBCUTANEOUS INJ ANEMIA RETACRIT SOLN EPOETIN ALFA-EPBX INJ ANTI-GOUT AGENT KRYSTEXXA SOLN PEGLOTICASE INJ (FOR IV INFUSION) ANTI-INFECTIVE PREVYMIS SOLN LETERMOVIR IV SOLN ANTI-INFECTIVE PREVYMIS TABS LETERMOVIR TAB ASTHMA CINQAIR SOLN RESLIZUMAB IV INFUSION SOLN ASTHMA FASENRA SOSY BENRALIZUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE ASTHMA FASENRA PEN SOAJ BENRALIZUMAB SUBCUTANEOUS SOLN AUTO-INJECTOR ASTHMA NUCALA SOAJ MEPOLIZUMAB SUBCUTANEOUS SOLUTION AUTO-INJECTOR ASTHMA NUCALA SOLR MEPOLIZUMAB FOR INJ ASTHMA NUCALA SOSY MEPOLIZUMAB SUBCUTANEOUS SOLUTION PREF SYRINGE ASTHMA XOLAIR SOLR OMALIZUMAB FOR INJ ASTHMA XOLAIR SOSY OMALIZUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE CARDIOVASCULAR VYNDAMAX CAPS TAFAMIDIS CAP CARDIOVASCULAR VYNDAQEL CAPS TAFAMIDIS MEGLUMINE (CARDIAC) CAP CENTRAL NERVOUS SYSTEM AGENTS AUSTEDO TABS DEUTETRABENAZINE TAB CENTRAL NERVOUS SYSTEM AGENTS ENSPRYNG SOSY SATRALIZUMAB-MWGE SUBCUTANEOUS SOLN PREF SYRINGE CENTRAL NERVOUS SYSTEM AGENTS HETLIOZ CAPS TASIMELTEON CAPSULE CENTRAL NERVOUS SYSTEM AGENTS HETLIOZ LQ SUSP TASIMELTEON ORAL SUSP CHEMOTHERAPY PROTECTANT AMIFOSTINE SOLR AMIFOSTINE CRYSTALLINE FOR INJ CHEMOTHERAPY PROTECTANT ELITEK
    [Show full text]
  • Preferred Drug List (Formulary)
    January 2020 Molina Healthcare of Michigan Preferred Drug List (Formulary) 1 Molina Healthcare of Michigan Preferred Drug List (Formulary) (01/01/2020) INTRODUCTION ..........................................................................................................................................................................................................................................5 PREFACE .....................................................................................................................................................................................................................................................5 PHARMACY AND THERAPEUTICS (P&T) COMMITTEE ..........................................................................................................................................................................5 DRUG LIST PRODUCT DESCRIPTIONS ...................................................................................................................................................................................................5 GENERIC SUBSTITUTION ..........................................................................................................................................................................................................................5 PLAN DESIGN .............................................................................................................................................................................................................................................6
    [Show full text]
  • September 2017 ~ Resource #330909
    −This Clinical Resource gives subscribers additional insight related to the Recommendations published in− September 2017 ~ Resource #330909 Medications Stored in the Refrigerator (Information below comes from current U.S. and Canadian product labeling and is current as of date of publication) Proper medication storage is important to ensure medication shelf life until the manufacturer expiration date and to reduce waste. Many meds are recommended to be stored at controlled-room temperature. However, several meds require storage in the refrigerator or freezer to ensure stability. See our toolbox, Medication Storage: Maintaining the Cold Chain, for helpful storage tips and other resources. Though most meds requiring storage at temperatures colder than room temperature should be stored in the refrigerator, expect to see a few meds require storage in the freezer. Some examples of medications requiring frozen storage conditions include: anthrax immune globulin (Anthrasil [U.S. only]), carmustine wafer (Gliadel [U.S. only]), cholera (live) vaccine (Vaxchora), dinoprostone vaginal insert (Cervidil), dinoprostone vaginal suppository (Prostin E2 [U.S.]), varicella vaccine (Varivax [U.S.]; Varivax III [Canada] can be stored in the refrigerator or freezer), zoster vaccine (Zostavax [U.S.]; Zostavax II [Canada] can be stored in the refrigerator or freezer). Use the list below to help identify medications requiring refrigerator storage and become familiar with acceptable temperature excursions from recommended storage conditions. Abbreviations: RT = room temperature Abaloparatide (Tymlos [U.S.]) Aflibercept (Eylea) Amphotericin B (Abelcet, Fungizone) • Once open, may store at RT (68°F to 77°F • May store at RT (77°F [25°C]) for up to Anakinra (Kineret) [20°C to 25°C]) for up to 30 days.
    [Show full text]
  • Michigan Department of Health and Human Services Practitioner and Medical Clinic Fee Schedule Revised: 04/06/2016 January - 2016
    Michigan Department of Health and Human Services Practitioner and Medical Clinic Fee Schedule Revised: 04/06/2016 January - 2016 Code Short Description Modifier Age Range Non Fac Fee Fac Fee Effective Date** 0054T Bone Srgry Cmptr Fluor Image NA $84.39 0055T Bone Srgry Cmptr Ct/Mri Imag NA $84.39 0178T 64 Lead Ecg W/I&R M M 0179T 64 Lead Ecg W/Tracing M M 0180T 64 Lead Ecg W/I&R Only M M 0190T Place Intraoc Radiation Src M M 0191T Insert Ant Segment Drain Int $379.27 $379.27 0195T Prescrl Fuse W/O Instr L5/S1 NA M 0196T Prescrl Fuse W/O Instr L4/L5 NA M 0198T Ocular Blood Flow Measure M M 0200T Perq Sacral Augmt Unilat Inj $987.92 $243.46 0201T Perq Sacral Augmt Bilat Inj $553.69 $120.64 0202T Post Vert Arthrplst 1 Lumbar $4,128.40 $288.24 0205T Inirs Each Vessel Add-On NA $63.19 0206T Cptr Dbs Alys Car Elec Dta $14.66 $14.66 0207T Clear Eyelid Gland W/Heat $136.47 $68.53 0208T Audiometry Air Only $17.43 NA 0209T Audiometry Air & Bone $20.80 NA 0210T Speech Audiometry Threshold $13.07 NA 0211T Speech Audiom Thresh & Recog $20.80 NA 0212T Compre Audiometry Evaluation $21.00 $18.42 0213T Njx Paravert W/Us Cer/Thor $107.57 $60.82 0214T Njx Paravert W/Us Cer/Thor $53.09 $34.47 0215T Njx Paravert W/Us Cer/Thor $53.29 $34.87 0216T Njx Paravert W/Us Lumb/Sac $97.66 $52.10 0217T Njx Paravert W/Us Lumb/Sac $48.93 $29.72 0218T Njx Paravert W/Us Lumb/Sac $49.13 $30.11 0219T Plmt Post Facet Implt Cerv $238.91 $129.56 0220T Plmt Post Facet Implt Thor $238.91 $129.56 0221T Plmt Post Facet Implt Lumb $236.14 $127.77 0222T Plmt Post Facet Implt Addl
    [Show full text]
  • Pharmaceutical Appendix to the Harmonized Tariff Schedule
    Harmonized Tariff Schedule of the United States Basic Revision 3 (2021) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States Basic Revision 3 (2021) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • CDER List of Licensed Biological Products With
    Center for Drug Evaluation and Research List of Licensed Biological Products with (1) Reference Product Exclusivity and (2) Biosimilarity or Interchangeability Evaluations to Date DATE OF FIRST REFERENCE PRODUCT DATE OF LICENSURE LICENSURE EXCLUSIVITY EXPIRY DATE INTERCHANGEABLE (I)/ BLA STN PRODUCT (PROPER) NAME PROPRIETARY NAME (mo/day/yr) (mo/day/yr) (mo/day/yr) BIOSIMILAR (B) WITHDRAWN 125118 abatacept Orencia 12/23/05 NA NA 103575 abciximab ReoPro 12/22/94 NA NA Yes 125274 abobotulinumtoxinA Dysport 04/29/09 125057 adalimumab Humira 12/31/02 NA NA 761071 adalimumab-adaz Hyrimoz 10/30/18 B 761058 adalimumab-adbm Cyltezo 08/25/17 B 761118 adalimumab-afzb Abrilada 11/15/19 B 761024 adalimumab-atto Amjevita 09/23/16 B 761059 adalimumab-bwwd Hadlima 07/23/19 B 125427 ado-trastuzumab emtansine Kadcyla 02/22/13 125387 aflibercept Eylea 11/18/11 103979 agalsidase beta Fabrazyme 04/24/03 NA NA 125431 albiglutide Tanzeum 04/15/14 017835 albumin chromated CR-51 serum Chromalbin 02/23/76 103293 aldesleukin Proleukin 05/05/92 NA NA 103948 alemtuzumab Campath, Lemtrada 05/07/01 NA NA 125141 alglucosidase alfa Myozyme 04/28/06 NA NA 125291 alglucosidase alfa Lumizyme 05/24/10 125559 alirocumab Praluent 07/24/15 103172 alteplase, cathflo activase Activase 11/13/87 NA NA 103950 anakinra Kineret 11/14/01 NA NA 020304 aprotinin Trasylol 12/29/93 125513 asfotase alfa Strensiq 10/23/15 101063 asparaginase Elspar 01/10/78 NA NA 125359 asparaginase erwinia chrysanthemi Erwinaze 11/18/11 761034 atezolizumab Tecentriq 05/18/16 761049 avelumab Bavencio 03/23/17
    [Show full text]
  • Michigan Department of Health and Human Services Practitioner and Medical Clinic Fee Schedule July - 2015 Revised: 09/30/2015 9:58:24 AM
    Michigan Department of Health and Human Services Practitioner and Medical Clinic Fee Schedule July - 2015 Revised: 09/30/2015 9:58:24 AM Code Short Description Modifier Age Range Non Fac Fee Fac Fee Effective Date** 0054T Bone Srgry Cmptr Fluor Image NA $78.63 0055T Bone Srgry Cmptr Ct/Mri Imag NA $78.63 0099T Implant Corneal Ring M M 0178T 64 Lead Ecg W/I&R M M 0179T 64 Lead Ecg W/Tracing M M 0180T 64 Lead Ecg W/I&R Only M M 0182T Hdr Elect Brachytherapy M NA 0182T Hdr Elect Brachytherapy 26 M M 0182T Hdr Elect Brachytherapy TC M NA 0190T Place Intraoc Radiation Src M M 0191T Insert Ant Segment Drain Int M M 0195T Prescrl Fuse W/O Instr L5/S1 M M 0196T Prescrl Fuse W/O Instr L4/L5 M M 0198T Ocular Blood Flow Measure M M 0200T Perq Sacral Augmt Unilat Inj NA $322.66 0201T Perq Sacral Augmt Bilat Inj $484.00 $484.00 0202T Post Vert Arthrplst 1 Lumbar NA $854.70 0205T Inirs Each Vessel Add-On NA $63.19 0206T Cptr Dbs Alys Car Elec Dta $10.89 $10.89 0207T Clear Eyelid Gland W/Heat $136.47 $68.53 0208T Audiometry Air Only $17.23 NA 0209T Audiometry Air & Bone $20.60 NA 0210T Speech Audiometry Threshold $12.88 NA 0211T Speech Audiom Thresh & Recog $20.80 NA 0212T Compre Audiometry Evaluation $20.80 $18.03 0213T Njx Paravert W/Us Cer/Thor $107.17 $61.01 0214T Njx Paravert W/Us Cer/Thor $52.69 $34.27 0215T Njx Paravert W/Us Cer/Thor $53.09 $34.67 0216T Njx Paravert W/Us Lumb/Sac $96.67 $51.70 0217T Njx Paravert W/Us Lumb/Sac $48.73 $29.52 0218T Njx Paravert W/Us Lumb/Sac $48.93 $29.91 0219T Plmt Post Facet Implt Cerv NA $410.61 0220T Plmt Post
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Injectable Medication Hcpcs/Dofr Crosswalk
    INJECTABLE MEDICATION HCPCS/DOFR CROSSWALK HCPCS DRUG NAME GENERIC NAME PRIMARY CATEGORY SECONDARY CATEGORY J0287 ABELCET Amphotericin B lipid complex THERAPEUTIC INJ HOME HEALTH/INFUSION** J0400 ABILIFY Aripiprazole, intramuscular, 0.25 mg THERAPEUTIC INJ J0401 ABILIFY MAINTENA Apriprazole 300mg, IM injection THERAPEUTIC INJ J9264 ABRAXANE paclitaxel protein-bound particles, 1 mg J1120 ACETAZOLAMIDE SODIUM Acetazolamide sodium injection THERAPEUTIC INJ J0132 ACETYLCYSTEINE INJ Acetylcysteine injection, 10 mg THERAPEUTIC INJ ACTEMRA INJECTION (50242-0136-01, J3262 50242-0137-01) Tocilizumab 200mg, 400mg THERAPEUTIC INJ ACTEMRA 162mg/0.9ml Syringe (50242- J3262 SELF-INJECTABLE 0138-01) Tocilizumab, 1 mg J0800 ACTHAR HP Corticotropin injection THERAPEUTIC INJ Hemophilus influenza b vaccine (Hib), PRP-T conjugate (4- 90648 ACTHIB dose schedule), for intramuscular use THERAPEUTIC INJ IMMUNIZATIONS J0795 ACTHREL Corticorelin ovine triflutal THERAPEUTIC INJ J9216 ACTIMMUNE Interferon gamma 1-b 3 miillion units SELF-INJECTABLE CHEMO ADJUNCT* J2997 ACTIVASE Alteplase recombinant, 1mg THERAPEUTIC INJ HOME HEALTH/INFUSION** J0133 ACYCLOVIR SODIUM Acyclovir, 5 mg THERAPEUTIC INJ HOME HEALTH/INFUSION** 90715 ADACEL Tdap vaccine, > 7 yrs, IM THERAPEUTIC INJ IMMUNIZATIONS J2504 ADAGEN Pegademase bovine, 25 IU THERAPEUTIC INJ HOME HEALTH/INFUSION** J9042 ADCETRIS Brentuximab vedotin Injection THERAPEUTIC INJ CHEMOTHERAPY J0153 ADENOCARD Adenosine 6 MG THERAPEUTIC INJ J0171 ADRENALIN Adrenalin (epinephrine) inject THERAPEUTIC INJ J9000 ADRIAMYCIN Doxorubicin
    [Show full text]